One of the early Target ALS-supported consortia studying C9orf72 ALS put forward the idea that it may be possible to treat ALS by targeting C9orf72 peptides directly. To move this idea forward, Target ALS connected Neurimmune, a biotechnology company with a group of scientists with niche expertise in cellular and animal models of ALS. Target ALS then funded this new collaboration to accelerate the development of antibodies against C9orf72, which were tested in mouse models of the disease.

At the 2018 Annual Meeting of Target ALS, Neurimmune announced the development of a potential therapeutic option and discussed plans to launch a Phase I clinical trial on an accelerated schedule.